DAM
REGN icon

Diamant Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Diamant Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-250
Closed -$206K – 70
2023
Q3 		$206K Buy
+250
New +$196K 0.17% 68

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Diamant Asset Management's REGN Position: Q4 2023 in Review

Diamant Asset Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2023, closing a stake of 250 shares — an estimated $206K sold.

Diamant Asset Management first reported a position in REGN in Q3 2023 and held it in 1 quarter. The position peaked at $206K in Q3 2023. 1,272 funds tracked by Wall St. Rank hold REGN as of Q4 2023.

  • Diamant Asset Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Diamant Asset Management sold 250 Regeneron Pharmaceuticals shares in Q4 2023, an estimated $206K.
  • Diamant Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Diamant Asset Management's Regeneron Pharmaceuticals position peaked at $206K in Q3 2023.
  • 1,272 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2023.

Based on Diamant Asset Management's 13F filing for Q4 2023, filed 13 Feb 2024.